In Ovo vaccine against infectious bursal disease
AssigneeUniversity of Maryland Biotechnology Institute
InventorVikram Vakharia
Life of this patent
Estimating the term…
Abstract
The present invention relates to a non pathogenic vaccine comprising a recombinant Infectious Bursal Disease virus that includes a recombinant Segment A, designated as rD78GLSNSΔ, that includes sequences from D78 and GLS strains and wherein the NS protein is not expressed.
Claims9
A recombinant Infectious Bursal Disease virus (IBDV) in ovo in a poultry ovum containing poultry maternal antibodies, comprising at least SEQ ID NO:
- 5 as Segment A of the IBDV, wherein SEQ ID NO:
- 5 includes nucleotide sequences from D78 of and GLS strains, and wherein SEQ ID NO:
- 5 does not express a NS protein.
A non-pathogenic vaccine in an embryonated poultry egg, said non-pathogenic vaccine comprising a recombinant IBDV comprising at least SEQ ID NO:
- 5 as Segment A of the IBDV, wherein SEQ ID NO:
- 5 includes nucleotide sequences from D78 and GLS strains, wherein the recombinant IBDV is not neutralized by maternal antibodies present in an embryo of said embryonated poultry egg, wherein the recombinant IBDV is non-lethal to said embryo, and wherein SEQ ID NO:
- 5 does not express a NS protein.
An in ova method of vaccination of poultry in the presence of maternal immunity against IBDV, the method comprising:
- introducing in ovo a vaccine comprising a recombinant Infectious Bursal Disease virus (IBDV) comprising at least Segment A (SEQ ID NO:
- 5) modified to include nucleotide sequence from D78 and GLS strains, and wherein SEQ ID NO. 5 does not express a NS protein and wherein the vaccaine is delivered in an amount sufficient to protect against STC-IBDV challenge.
A live, non-pathogenic recombinant IBD virus in ovo in a poultry ovum containing poultry maternal antibodies, wherein the live, non-pathogenic recombinant IBD virus is present in said ovum in a sufficient amount to protect the ovum against IBD challenge in the presence of said poultry maternal antibodies, and wherein the live, non-pathogenic recombinant IBD virus has been produce by the method comprising the following steps:
- (a) preparing cDNA of infectious bursal disease virus genome segments A and B, wherein the segment A comprises SEQ ID NO:
- 5 wherein the cDNA contains epitopic determinants from D78 and/or GLS strains, and wherein SEQ ID NO. 5 does not express a NS protein;
- (b) transcribing said cDNA to produce synthetic RNA transcripts,
- (c) transfecting host cells with said synthetic RNA transcripts,
- (d) incubating said host cells in a culture medium, and
- (e) isolating live, nonpathogenic, infectious bursal disease virus from said culture medium.
Dependencies are inferred from the claim text.